(Bloomberg) Rodman & Renshaw reiterates outperform recommendation on EpiCept on the grounds that the company is in discussion with major pharmaceutical companies about partnerships around the NP-1 and a new U.S. study on Ceplene.
The target price is $ 2, corresponding to 12:60 crowns, implying a substantial upside compared to Monday's closing price of SEK 4:11.
According to a market letter on Tuesday.
Recently reported Epicept positive results from a placebo-controlled phase 2 study of NP-1 under the leadership of the National Cancer Institute. The study showed that NP-1 had significant impairment compared to placebo and talks with large pharmaceutical companies will then have intensified.
"According to EpiCept's leadership, several major pharmaceutical companies involved in an ongoing dialogue, and we believe that a partnership for NP-1 will meet in 2011," said Rodman & Renshaw.
EpiCept is also designing a new phase 3 study to evaluate Ceplene in combination with low dose interleukin-2 (IL-2).
"The new study is based in part on data submitted in an application to the FDA last year, which showed a strong trend for Ceplene against standard treatment in terms of overall survival," said Rodman & Renshaw.